新生儿万古霉素群体药动学模型的外部评估:从一阶方程到贝叶斯引导的治疗监测
本研究外部评估了28个新生儿万古霉素群体药动学模型,数据来自72名新生儿和380个浓度点。贝叶斯方法与参考暴露值一致性超过75%。
要点
- Capparelli和Mehrotra模型预测性能最佳,不精确度分别为16.8%和16.9%。
- 贝叶斯方法与参考暴露值一致性超过75%,可减少采血次数。
- 最佳模型推荐的首剂方案高于现行理论列线图,以促进达标。
核心结论
- Capparelli和Mehrotra模型在新生儿万古霉素群体药动学模型中预测性能最佳。
- 贝叶斯方法与参考暴露值一致性超过75%,可减少达标时间和采血次数。
研究设计与样本
- 外部评估研究,纳入72名新生儿和380个万古霉素浓度点,评估28个群体药动学模型。
主要发现
- Capparelli和Mehrotra模型不精确度最低,分别为16.8%和16.9%。
- 贝叶斯方法与参考暴露值一致性在大多数情况下超过75%。
- 最佳模型推荐的首剂方案高于现行理论列线图。
关键数值与推荐
- 预测性能可接受标准:偏差≤±15%,不精确度≤30%。
- Capparelli模型不精确度16.8%,Mehrotra模型不精确度16.9%。
临床怎么用
- 临床可采用Capparelli或Mehrotra模型进行贝叶斯治疗监测。
- 贝叶斯方法可减少新生儿采血次数并加快达标。
- 初始剂量可参考最佳模型衍生的列线图,可能高于现行理论方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Guidelines for vancomycin therapeutic monitoring recommend using a Bayesian approach with a population pharmacokinetic model to estimate the 24 h area under the concentration-time curve over first-order equations. Thus, we performed an external evaluation of population pharmacokinetic models of vancomycin in neonates and compared Bayesian results with those observed in clinical practice via pharmacokinetic equations to improve therapeutic monitoring by proposing optimized initial dosing nomograms and assessing the feasibility of reduced blood sampling strategies using the most predictive models. METHODS: Models were identified from the literature and evaluated via an external neonatal population. A priori predictive performance was first assessed by prediction-based diagnostics, then by simulation-based diagnostics and a posteriori analyses only if deemed satisfactory; model-informed vancomycin exposure was also compared with reference first-order pharmacokinetic equations. The best-performing models were ultimately subjected to Monte Carlo simulations to develop new initial dosing nomograms offering the highest probability of achieving therapeutic target. RESULTS: A total of 28 population pharmacokinetic models were evaluated in the external dataset, which includes 72 neonates and 380 vancomycin concentrations. Eleven models had an adequate predictive performance with bias ≤ ± 15% and imprecision ≤ 30%, while the Bayesian approach yielded over 75% agreement with reference exposure values in most cases. Nonetheless, Capparelli et al. and Mehrotra et al. models performed the best overall, showing the lowest imprecisions of 16.8% and 16.9%, respectively; both models recommended higher dosage regimens than the theoretical nomogram currently applied to favor therapeutic target attainment. DISCUSSION: We externally evaluated numerous neonatal population pharmacokinetic models of vancomycin and used the most predictive ones to advocate new initial dosing nomograms. Clinical implementation of the Bayesian approach could reduce the time needed to reach therapeutic target and limit the number of blood samples in newborns compared with traditional pharmacokinetic equations.
引用
- Blouin M, Métras MÉ, Gaudreault C, et al. External evaluation of neonatal vancomycin population pharmacokinetic models: Moving from first-order equations to Bayesian-guided therapeutic monitoring. Pharmacotherapy. 2024. PMID: 39544156. doi:10.1002/phar.4623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。